Seth Loring Harrison - 08 Jun 2021 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role: Director, 10%+ Owner
Signature: /s/ Stephen Tulipano, Attorney-in-Fact
Issuer symbol: STOK
Transactions as of: 08 Jun 2021
Net transactions value: $0
Form type: 4
Filing time: 25 Jun 2021, 16:57:20 UTC
Previous filing: 03 Jun 2021
Next filing: 03 Jun 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	STOK	Director Stock Option (Right to Buy)	Award	$0	+11,650		$0.000000	11,650	08 Jun 2021	Common Stock	11,650	$40.37	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option shall fully vest on June 8, 2022 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date.
F2	Under the reporting person's arrangement with Apple Tree Life Sciences, Inc. (the "Manager"), the reporting person holds the option for the benefit of Apple Tree Partners IV, L.P. (the "Fund"). The reporting person is obligated to turn over to the Manager any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Manager. The reporting person therefore disclaims beneficial ownership of the option and underlying common stock.

Content

The option shall fully vest on June 8, 2022 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date.

Under the reporting person's arrangement with Apple Tree Life Sciences, Inc. (the "Manager"), the reporting person holds the option for the benefit of Apple Tree Partners IV, L.P. (the "Fund"). The reporting person is obligated to turn over to the Manager any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Manager. The reporting person therefore disclaims beneficial ownership of the option and underlying common stock.